94 related articles for article (PubMed ID: 12015701)
1. Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy.
Grimes RM; Otiniano ME; Rodriguez-Barradas MC; Lai D
Clin Infect Dis; 2002 Jun; 34(11):1530-3. PubMed ID: 12015701
[TBL] [Abstract][Full Text] [Related]
2. Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort.
Perez JL; Moore RD
Clin Infect Dis; 2003 Jan; 36(2):212-8. PubMed ID: 12522755
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
[TBL] [Abstract][Full Text] [Related]
4. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
5. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
[TBL] [Abstract][Full Text] [Related]
6. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
7. Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy.
Dufour V; Wislez M; Bergot E; Mayaud C; Cadranel J
Clin Infect Dis; 2003 May; 36(10):e127-30. PubMed ID: 12746792
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
9. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
10. Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.
Sterling TR; Chaisson RE; Moore RD
Clin Infect Dis; 2003 Mar; 36(6):812-5. PubMed ID: 12627368
[TBL] [Abstract][Full Text] [Related]
11. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
13. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005.
Buchacz K; Baker RK; Moorman AC; Richardson JT; Wood KC; Holmberg SD; Brooks JT;
AIDS; 2008 Jul; 22(11):1345-54. PubMed ID: 18580614
[TBL] [Abstract][Full Text] [Related]
14. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank.
Morgello S; Estanislao L; Simpson D; Geraci A; DiRocco A; Gerits P; Ryan E; Yakoushina T; Khan S; Mahboob R; Naseer M; Dorfman D; Sharp V;
Arch Neurol; 2004 Apr; 61(4):546-51. PubMed ID: 15096404
[TBL] [Abstract][Full Text] [Related]
15. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.
European Collaborative Study
Clin Infect Dis; 2005 Feb; 40(3):458-65. PubMed ID: 15668871
[TBL] [Abstract][Full Text] [Related]
16. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
17. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ;
J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358
[TBL] [Abstract][Full Text] [Related]
19. The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study).
Vellozzi C; Brooks JT; Bush TJ; Conley LJ; Henry K; Carpenter CC; Overton ET; Hammer J; Wood K; Holmberg SD;
Am J Epidemiol; 2009 Mar; 169(5):642-52. PubMed ID: 19074775
[TBL] [Abstract][Full Text] [Related]
20. Gastroduodenal opportunistic infections and dyspepsia in HIV-infected patients in the era of Highly Active Antiretroviral Therapy.
Werneck-Silva AL; Prado IB
J Gastroenterol Hepatol; 2009 Jan; 24(1):135-9. PubMed ID: 19054257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
